An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. BRAF inhibitor GSK2118436 selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
Leave a Comment
You must be logged in to post a comment.